Aktis-101

Aktis-101 is a preclinical-stage targeted alpha therapy (TAT) radioconjugate being developed by Aktis Oncology for the treatment of solid tumors. As a radiopharmaceutical, it is designed to deliver potent alpha-emitting radioisotopes directly to cancer cells using a high-affinity binder, likely a miniprotein based on the company's proprietary platform. The mechanism of action involves the emission of high-energy alpha particles that induce lethal double-strand DNA breaks within the targeted tumor cells, while the short range of the alpha radiation helps to minimize damage to surrounding healthy tissues. The specific molecular target for Aktis-101 has not been publicly disclosed by the sponsor.